Request a Quotation

Your Contact Information
Peptides Logo
Support and counselling under:
+49(0)3302 - 2022000 info@peptides.de
€0.00*
Structure of EBV LMP2 419-427 mutant 426S (HLA-A*24:02)
Logo for Infectious disease
Infectious disease

EBV LMP2 419-427 mutant 426S (HLA-A*24:02) TYGPVFMSL

Product number: EP11158_1

€105.00*

Prices excl. VAT plus shipping costs
Available, delivery time: 3 weeks
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS
Caution: For research use only. Not for use in humans.
Amount in mg
1
Add to Cart

Description

The peptide EBV LMP2 419-427 mutant 426S (HLA-A*24:02) with the amino acid sequence TYGPVFMSL is a linear peptidic epitope (epitope ID 67350) studied as part of Latent membrane protein 2 (UniProt:P13285) from Human herpesvirus 4 (Epstein Barr virus).

EBV LMP2 419-427 mutant 426S (HLA-A*24:02) has been studied for immune reactivity in publications and has been tested in T cell assays and MHC ligand assays.

TechData

Sequence: TYGPVFMSL
Gene: LMP2
Delivery: 3 weeks
C-Terminus: OH
N-Terminus: H
Amount: 1 mg
Counterion: TFA
Protein: Latent membrane protein
Species: Epstein-Barr virus (EBV; Human herpesvirus 4)
Allele: HLA-A*24:02
Application: T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response
Indication: Infectious disease, Cancer, Neuroscience
Purity: 95% HPLC-MS

Documents

Material data sheet Safety data sheet Storage and handling of peptides Probing of membranes with HRP
Skip product gallery

More EBV LMP peptides

EBV (LMP2) Peptide Pool
EBV (LMP2) Peptide Pool
The EBV (LMP2) Peptide Pool from peptides&elephants is designed for advanced T cell stimulation and epitope mapping in immunological studies of Epstein-Barr virus (EBV, HHV-4). This peptide pool consists of 122 synthetic 15-mer peptides, overlapping by 11 amino acids, and covers the full sequence of the Latent Membrane Protein 2 (LMP2) (UniProt ID: P13285). LMP2 is a latency-associated antigen commonly expressed in EBV-related malignancies such as nasopharyngeal carcinoma and Hodgkin’s lymphoma. It is a known target of both CD4⁺ and CD8⁺ T cell responses. Each unit of the peptide pool allows for the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is optimized for use in T cell assays, such as ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based functional readouts. Scientific Background LMP2 is one of the most clinically relevant antigens for therapeutic EBV vaccine development, particularly in the context of EBV-associated cancers such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease (PTLD). Therapeutic vaccine candidates using viral vectors encoding LMP2 have successfully induced virus-specific CD8⁺ T cell responses in early-phase clinical trials. Furthermore, adoptive T cell therapies like posoleucel also target LMP2 alongside other latency proteins such as EBNA1, reinforcing its significance as a conserved and immunodominant antigen. This peptide pool is an ideal tool for: Characterizing patient-specific or vaccine-induced T cell responses Ex vivo stimulation of EBV-specific T cells Epitope screening and immune profiling Immune monitoring in clinical trials of EBV-targeted vaccines or adoptive T cell therapies

€340.70*
EBV LMP-1 125-133 (HLA-A*02:01)
EBV LMP-1 125-133 (HLA-A*02:01)
Antigen Peptide EBV LMP-1 125-133 (HLA-A*02:01) YLLEMLWRL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP-2 340-349 (HLA-A*11:01)
EBV LMP-2 340-349 (HLA-A*11:01)
SSCSSCPLSK is a linear peptidic epitope (epitope ID60930) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*
Details
EBV LMP-2 340-349 mutant (HLA-A*11:01) 348T
EBV LMP-2 340-349 mutant (HLA-A*11:01) 348T
SSCSSCPLTK is a linear mutated peptidic epitope (epitope ID60930) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assay

From €105.00*
Details
EBV LMP-2 419-427 (HLA-A*24:02)
EBV LMP-2 419-427 (HLA-A*24:02)
Antigen Peptide EBV LMP-2 419-427 (HLA-A*24:02) TYGPVFMCL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP-2 426-434 (HLA-A*02:01)
EBV LMP-2 426-434 (HLA-A*02:01)
EBV LMP-2 426-434 (HLA-A*02:01) CLGGLLTMV for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP1 159-167 (HLA-A*02:01)
EBV LMP1 159-167 (HLA-A*02:01)
Antigen Peptide EBV LMP1 159-167 (HLA-A*02:01) YLQQNWWTL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP2 131-139 (HLA-A*24:02)
EBV LMP2 131-139 (HLA-A*24:02)
Single peptide (PYLFWLAAI) for stimulation of human EBV LMP2(131-139)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*2402 allele.

From €105.00*
Details
EBV LMP2 200-208 (HLA-B*40:01)
EBV LMP2 200-208 (HLA-B*40:01)
IEDPPFNSL is a linear peptidic epitope (epitope ID 25756) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*
Details
EBV LMP2 356-364 (HLA-A*02:01)
EBV LMP2 356-364 (HLA-A*02:01)
Antigen Peptide EBV LMP2 HLA-A*0201 (FLYALALLL) for stimulation of human EBV LMP2(356-364)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. LYALALLL is a linear peptidic epitope studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus).

From €105.00*
Details
This website uses cookies to ensure the best experience possible. More information...